Advertisement

Update on the National Vaccine Injury Compensation Program

      Abstract

      The National Childhood Vaccine Injury Act of 1986, as amended, established the Vaccine Injury Compensation Program (VICP). The VICP went into effect on October 1, 1988 and is a Federal “no-fault” system designed to compensate individuals, or families of individuals, who have been injured by covered vaccines. From 1988 until July 2006, a total of 2531 non-autism/thimerosal and 5030 autism/thimerosal claims were made to the VICP. The compensation paid for the non-autism/thimerosal claims from 1988 until 2006 was $902,519,103.37 for 2542 awards. There was no compensation for any of the autism/thimerosal claims. On the basis of the deaths and extensive suffering to patients and families from the adverse reactions to vaccines, all physicians must provide detailed information in the Vaccine Information Statement to the patient or the parent or legal guardian of the child about the potential dangers of vaccines as well as the VICP.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Emergency Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Davis T.C.
        • Fredrickson D.D.
        • Kennen E.M.
        • et al.
        Childhood vaccine risk/benefit communication among public health clinics: a time-motion study.
        Public Health Nurs. 2004; 21: 228-236
        • Edlich R.F.
        • Martin M.L.
        • Foley M.L.
        • et al.
        Vaccine information statements.
        J Long Term Eff Med Implants. 2005; 15: 91-114
      1. National Childhood Vaccine Injury Act Vaccine Injury Table. Available at. http://www.hrsa.gov/vaccinecompensation/table.htm. Accessed 2006.

        • Blaxill M.F.
        What’s going on?.
        Public Heath Rep. 2004; 119: 536-551
        • Gerlai R.
        • Gerlai J.
        Autism: a target of pharmacotherapies?.
        Drug Discov Today. 2004; 9: 366-374
        • Gerlai J.
        • Gerlai R.
        Autism: a large unmet medical need and a complex research problem.
        Physiol Behav. 2003; 79: 461-470
        • Bertrand J.
        • Mars A.
        • Boyle C.
        • Bove F.
        • Yeargin-Allsopp M.
        • Decoufle P.
        Prevalence of autism in a United States population: the Brick Township, New Jersey, investigation.
        Pediatrics. 2001; 108: 1155-1161
        • Yeargin-Allsopp M.
        • Rice C.
        • Karapurkar T.
        • Doernberg N.
        • Boyle C.
        • Murphy C.
        Prevalence of autism in a US metropolitan area.
        JAMA. 2003; 289: 49-55
        • California Department of Developmental Services
        Autistic Spectrum Disorders—Changes in the California Caseload—An Update 1999 through 2002. State of California, Sacramento, CA2003
        • Ball L.K.
        • Ball R.
        • Pratt R.D.
        An assessment of thimerosal use in childhood vaccines.
        Pediatrics. 2001; 107: 1147-1154
        • Bernard S.
        • Enayati A.
        • Redwood L.
        • Roger H.
        • Binstock T.
        Autism: a novel form of mercury poisoning.
        Med Hypotheses. 2001; 56: 462-471
        • Bernard S.
        • Enayati A.
        • Roger H.
        • Binstock T.
        • Redwood L.
        The role of mercury in the pathogenesis of autism.
        Mol Psychiatry. 2002; 7: S42-S43
        • Blaxill M.F.
        • Redwood L.
        • Bernard S.
        Thimerosal and autism?.
        Med Hypotheses. 2004; 62: 788-794
        • Geier D.A.
        • Geier M.R.
        A two-phased population epidemiological study of the safety of thimerosal-containing vaccines: a follow-up analysis.
        Med Sci Monit. 2005; 11: CR160-CR170
      2. Vaccine Compensation Statistics Table. Available at. http://www.hrsa.gov/vaccinecompensation/statistics_report.htm#post_1988.